Literature DB >> 26421998

Site-Directed Mutagenesis of Surface-Exposed Lysine Residues Leads to Improved Transduction by AAV2, But Not AAV8, Vectors in Murine Hepatocytes In Vivo.

Baozheng Li1, Wenqin Ma1, Chen Ling1,2,3, Kim Van Vliet4, Lin-Ya Huang4, Mavis Agbandje-McKenna2,3,4, Arun Srivastava1,2,3,5,6, George V Aslanidi1,2,3.   

Abstract

The ubiquitin-proteasome pathway plays a critical role in the intracellular trafficking of recombinant adeno-associated virus 2 (AAV2) vectors, which negatively impacts the transduction efficiency of these vectors. Because ubiquitination occurs on lysine (K) residues, we performed site-directed mutagenesis where we replaced each of 10 surface-exposed K residues (K258, K490, K507, K527, K532, K544, K549, K556, K665, and K706) with glutamic acid (E) because of similarity of size and lack of recognition by modifying enzymes. The transduction efficiency of K490E, K544E, K549E, and K556E scAAV2 vectors increased in HeLa cells in vitro up to 5-fold compared with wild-type (WT) AAV2 vectors, with the K556E mutant being the most efficient. Intravenous delivery of WT and K-mutant ssAAV2 vectors further corroborated these results in murine hepatocytes in vivo. Because AAV8 vectors transduce murine hepatocytes exceedingly well, and because some of the surface-exposed K residues are conserved between these serotypes, we generated and tested two single mutants (K547E and K569E), and one double-mutant (K547 + 569E) AAV8 vector. However, no significant increase in the transduction efficiency of any of these mutant AAV8 vectors was observed in murine hepatocytes in vivo. These studies suggest that although targeting the surface-exposed K residues is yet another strategy to improve the transduction efficiency of AAV vectors, phenotypic outcome is serotype specific.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26421998      PMCID: PMC4677520          DOI: 10.1089/hgtb.2015.115

Source DB:  PubMed          Journal:  Hum Gene Ther Methods        ISSN: 1946-6536            Impact factor:   2.396


  38 in total

1.  PyMod: sequence similarity searches, multiple sequence-structure alignments, and homology modeling within PyMOL.

Authors:  Emanuele Bramucci; Alessandro Paiardini; Francesco Bossa; Stefano Pascarella
Journal:  BMC Bioinformatics       Date:  2012-03-28       Impact factor: 3.169

2.  Bioengineering of AAV2 capsid at specific serine, threonine, or lysine residues improves its transduction efficiency in vitro and in vivo.

Authors:  Nishanth Gabriel; Sangeetha Hareendran; Dwaipayan Sen; Rupali A Gadkari; Govindarajan Sudha; Ruchita Selot; Mansoor Hussain; Ramya Dhaksnamoorthy; Rekha Samuel; Narayanaswamy Srinivasan; Alok Srivastava; Giridhara R Jayandharan
Journal:  Hum Gene Ther Methods       Date:  2013-03-15       Impact factor: 2.396

3.  Human hepatocyte growth factor receptor is a cellular coreceptor for adeno-associated virus serotype 3.

Authors:  Chen Ling; Yuan Lu; Jasmine K Kalsi; Giridhara R Jayandharan; Baozheng Li; Wenqin Ma; Binbin Cheng; Samantha W Y Gee; Katherine E McGoogan; Lakshmanan Govindasamy; Li Zhong; Mavis Agbandje-McKenna; Arun Srivastava
Journal:  Hum Gene Ther       Date:  2010-12       Impact factor: 5.695

4.  Optimizing the transduction efficiency of capsid-modified AAV6 serotype vectors in primary human hematopoietic stem cells in vitro and in a xenograft mouse model in vivo.

Authors:  Liujiang Song; M Ariel Kauss; Etana Kopin; Manasa Chandra; Taihra Ul-Hasan; Erin Miller; Giridhara R Jayandharan; Angela E Rivers; George V Aslanidi; Chen Ling; Baozheng Li; Wenqin Ma; Xiaomiao Li; Lourdes M Andino; Li Zhong; Alice F Tarantal; Mervin C Yoder; Kamehameha K Wong; Mengqun Tan; Saswati Chatterjee; Arun Srivastava
Journal:  Cytotherapy       Date:  2013-08       Impact factor: 5.414

5.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

Review 6.  Immune responses to AAV vectors: overcoming barriers to successful gene therapy.

Authors:  Federico Mingozzi; Katherine A High
Journal:  Blood       Date:  2013-04-17       Impact factor: 22.113

7.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection.

Authors:  Carmela Zincarelli; Stephen Soltys; Giuseppe Rengo; Joseph E Rabinowitz
Journal:  Mol Ther       Date:  2008-04-15       Impact factor: 11.454

8.  Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses.

Authors:  Li Zhong; Baozheng Li; Cathryn S Mah; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Mario Cooper; Roland W Herzog; Irene Zolotukhin; Kenneth H Warrington; Kirsten A Weigel-Van Aken; Jacqueline A Hobbs; Sergei Zolotukhin; Nicholas Muzyczka; Arun Srivastava
Journal:  Proc Natl Acad Sci U S A       Date:  2008-05-29       Impact factor: 11.205

9.  A dual role of EGFR protein tyrosine kinase signaling in ubiquitination of AAV2 capsids and viral second-strand DNA synthesis.

Authors:  Li Zhong; Weihong Zhao; Jianqing Wu; Baozheng Li; Sergei Zolotukhin; Lakshmanan Govindasamy; Mavis Agbandje-McKenna; Arun Srivastava
Journal:  Mol Ther       Date:  2007-04-17       Impact factor: 11.454

10.  Adenovirus-associated virus vector-mediated gene transfer in hemophilia B.

Authors:  Amit C Nathwani; Edward G D Tuddenham; Savita Rangarajan; Cecilia Rosales; Jenny McIntosh; David C Linch; Pratima Chowdary; Anne Riddell; Arnulfo Jaquilmac Pie; Chris Harrington; James O'Beirne; Keith Smith; John Pasi; Bertil Glader; Pradip Rustagi; Catherine Y C Ng; Mark A Kay; Junfang Zhou; Yunyu Spence; Christopher L Morton; James Allay; John Coleman; Susan Sleep; John M Cunningham; Deokumar Srivastava; Etiena Basner-Tschakarjan; Federico Mingozzi; Katherine A High; John T Gray; Ulrike M Reiss; Arthur W Nienhuis; Andrew M Davidoff
Journal:  N Engl J Med       Date:  2011-12-10       Impact factor: 176.079

View more
  15 in total

1.  Adeno-Associated Virus: The Naturally Occurring Virus Versus the Recombinant Vector.

Authors:  Arun Srivastava
Journal:  Hum Gene Ther       Date:  2016-01       Impact factor: 5.695

2.  SUMOylation Targets Adeno-associated Virus Capsids but Mainly Restricts Transduction by Cellular Mechanisms.

Authors:  Qingxin Chen; Robin Njenga; Barbara Leuchs; Susanna Chiocca; Jürgen Kleinschmidt; Martin Müller
Journal:  J Virol       Date:  2020-09-15       Impact factor: 5.103

3.  An essential N-terminal serine-rich motif in the AAV VP1 and VP2 subunits that may play a role in viral transcription.

Authors:  Tawana M Robinson; Michelle L Ho; Brian Wahlig; Veronica Gough; Anton Banta; Kiara Reyes Gamas; Byunguk Kang; Esther Lee; Weitong Chen; Junghae Suh
Journal:  Virology       Date:  2020-04-25       Impact factor: 3.616

Review 4.  Next Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases.

Authors:  Kenneth I Berns; Arun Srivastava
Journal:  Gastroenterol Clin North Am       Date:  2019-04-01       Impact factor: 3.806

5.  Efficient Gene Delivery and Expression in Pancreas and Pancreatic Tumors by Capsid-Optimized AAV8 Vectors.

Authors:  Min Chen; Kyungah Maeng; Akbar Nawab; Rony A Francois; Julie K Bray; Mary K Reinhard; Sanford L Boye; William W Hauswirth; Frederic J Kaye; Georgiy Aslanidi; Arun Srivastava; Maria Zajac-Kaye
Journal:  Hum Gene Ther Methods       Date:  2017-02       Impact factor: 2.396

6.  Chemical modification of the adeno-associated virus capsid to improve gene delivery.

Authors:  Mathieu Mével; Mohammed Bouzelha; Aurélien Leray; Simon Pacouret; Mickael Guilbaud; Magalie Penaud-Budloo; Dimitri Alvarez-Dorta; Laurence Dubreil; Sébastien G Gouin; Jean Philippe Combal; Mirja Hommel; Gloria Gonzalez-Aseguinolaza; Véronique Blouin; Philippe Moullier; Oumeya Adjali; David Deniaud; Eduard Ayuso
Journal:  Chem Sci       Date:  2019-12-09       Impact factor: 9.825

Review 7.  Intracellular trafficking of adeno-associated virus (AAV) vectors: challenges and future directions.

Authors:  Jalish M Riyad; Thomas Weber
Journal:  Gene Ther       Date:  2021-03-03       Impact factor: 4.184

Review 8.  Gene Therapy 2017: Progress and Future Directions.

Authors:  A M Keeler; M K ElMallah; T R Flotte
Journal:  Clin Transl Sci       Date:  2017-05-23       Impact factor: 4.689

9.  Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models.

Authors:  David M Markusic; Timothy C Nichols; Elizabeth P Merricks; Brett Palaschak; Irene Zolotukhin; Damien Marsic; Sergei Zolotukhin; Arun Srivastava; Roland W Herzog
Journal:  J Transl Med       Date:  2017-05-01       Impact factor: 5.531

10.  Proteasome Inhibition Increases the Efficiency of Lentiviral Vector-Mediated Transduction of Trabecular Meshwork.

Authors:  Zeynep Aktas; Hongyu Rao; Sarah R Slauson; B'Ann T Gabelt; Inna V Larsen; Rachael T C Sheridan; Leonie Herrnberger; Ernst R Tamm; Paul L Kaufman; Curtis R Brandt
Journal:  Invest Ophthalmol Vis Sci       Date:  2018-01-01       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.